Novel treatments to prevent and treat hearing loss
In the US, 50 million are affected with hearing loss or tinnitus. Unfortunately, there are no FDA approved drugs that treat a single disease or disorder of the inner ear. We are developing the first therapeutics that will prevent and treat sensorineural hearing loss and tinnitus.
Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.
LEARN MORESEATTLE–(BUSINESS WIRE)–Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD).
Read More
SEATTLE–(BUSINESS WIRE)–Sound Pharmaceuticals (SPI) is pleased to announce that the FDA has granted its investigational new drug, SPI-1005, Breakthrough Therapy Designation (BTD) for the treatment of hearing loss in patients with Meniere’s disease (MD).
Read More
SEATTLE — Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at two upcoming industry conferences this month.
Read More
Oral treatments for acute and chronic hearing loss
Oral combination for the treatment of acute ototoxicity
LEARN MORELocally delivered treatments for hearing restoration
LEARN MORE
